Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $56.46, marking a -2.5% move from the previous day.
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $54.74, indicating a -2.2% shift from the previous trading day.
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%
Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy
CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad approvals, revenue growth is gradual due to complex treatment logistics and patient adoption hurdles. CRSP's pipeline includes promising in-vivo cardiovascular, CAR-T oncology/autoimmune, and diabetes programs, with key updates expected in 2025.
